These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors. Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584 [TBL] [Abstract][Full Text] [Related]
23. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Chhieng DC; Cangiarella JF; Zakowski MF; Goswami S; Cohen JM; Yee HT Cancer; 2001 Oct; 93(5):330-6. PubMed ID: 11668468 [TBL] [Abstract][Full Text] [Related]
24. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Agoff SN; Lamps LW; Philip AT; Amin MB; Schmidt RA; True LD; Folpe AL Mod Pathol; 2000 Mar; 13(3):238-42. PubMed ID: 10757334 [TBL] [Abstract][Full Text] [Related]
25. Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids. Pelosi G; Scarpa A; Puppa G; Veronesi G; Spaggiari L; Pasini F; Maisonneuve P; Iannucci A; Arrigoni G; Viale G Cancer; 2005 Mar; 103(6):1154-64. PubMed ID: 15712207 [TBL] [Abstract][Full Text] [Related]
26. Molecular markers help characterize neuroendocrine lung tumors. Rusch VW; Klimstra DS; Venkatraman ES Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011 [TBL] [Abstract][Full Text] [Related]
27. Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung. Song J; Li M; Tretiakova M; Salgia R; Cagle PT; Husain AN Arch Pathol Lab Med; 2010 Nov; 134(11):1702-5. PubMed ID: 21043826 [TBL] [Abstract][Full Text] [Related]
28. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Khoor A; Whitsett JA; Stahlman MT; Olson SJ; Cagle PT Hum Pathol; 1999 Jun; 30(6):695-700. PubMed ID: 10374779 [TBL] [Abstract][Full Text] [Related]
30. Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases. Zamecnik J; Kodet R Virchows Arch; 2002 Apr; 440(4):353-61. PubMed ID: 11956814 [TBL] [Abstract][Full Text] [Related]
31. Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Jiang SX; Kameya T; Sato Y; Yanase N; Yoshimura H; Kodama T Am J Pathol; 1996 Mar; 148(3):837-46. PubMed ID: 8774138 [TBL] [Abstract][Full Text] [Related]
32. Differential expression of forkhead box M1 and its downstream cyclin-dependent kinase inhibitors p27(kip1) and p21(waf1/cip1) in the diagnosis of pulmonary neuroendocrine tumours. Ha SY; Lee CH; Chang HK; Chang S; Kwon KY; Lee EH; Roh MS; Seo B Histopathology; 2012 Apr; 60(5):731-9. PubMed ID: 22296117 [TBL] [Abstract][Full Text] [Related]
33. Pulmonary Carcinoids and Low-Grade Gastrointestinal Neuroendocrine Tumors Show Common MicroRNA Expression Profiles, Different from Adenocarcinomas and Small Cell Carcinomas. Yoshimoto T; Motoi N; Yamamoto N; Nagano H; Ushijima M; Matsuura M; Okumura S; Yamaguchi T; Fukayama M; Ishikawa Y Neuroendocrinology; 2018; 106(1):47-57. PubMed ID: 28208131 [TBL] [Abstract][Full Text] [Related]
34. mASH1 is Highly Specific for Neuroendocrine Carcinomas: An Immunohistochemical Evaluation on Normal and Various Neoplastic Tissues. Altree-Tacha D; Tyrrell J; Li F Arch Pathol Lab Med; 2017 Feb; 141(2):288-292. PubMed ID: 27628324 [TBL] [Abstract][Full Text] [Related]
35. Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2. Gupta A; Yu X; Case T; Paul M; Shen MM; Kaestner KH; Matusik RJ Prostate; 2013 May; 73(6):582-9. PubMed ID: 23060003 [TBL] [Abstract][Full Text] [Related]
36. Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis. Sampietro G; Tomasic G; Collini P; Biganzoli E; Boracchi P; Bidoli P; Pilotti S Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):49-56. PubMed ID: 10937049 [TBL] [Abstract][Full Text] [Related]
37. Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Sholl LM; Long KB; Hornick JL Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):55-61. PubMed ID: 19661786 [TBL] [Abstract][Full Text] [Related]
38. Expression of thyroid transcription factor-1 in normal and neoplastic lung tissues. Nakamura N; Miyagi E; Murata S; Kawaoi A; Katoh R Mod Pathol; 2002 Oct; 15(10):1058-67. PubMed ID: 12379752 [TBL] [Abstract][Full Text] [Related]
39. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Bishop JA; Sharma R; Illei PB Hum Pathol; 2010 Jan; 41(1):20-5. PubMed ID: 19740516 [TBL] [Abstract][Full Text] [Related]
40. 34betaE12 cytokeratin immunodetection in the differential diagnosis of neuroendocrine carcinomas of the breast. Papotti M; Sapino A; Righi L; Chiappone S; Bussolati G Appl Immunohistochem Mol Morphol; 2001 Sep; 9(3):229-33. PubMed ID: 11556750 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]